Three biotechs re­veal some se­crets about them­selves as they gun for $271M-plus in IPOs

Last week end­ed with an­oth­er Fri­day night blitz of biotech S-1s as a fresh wave of new of­fer­ings forms to crash in­to Nas­daq. En­ter­ing the Wall Street spot­light now is one transat­lantic op­er­a­tion that is out to de­vel­op a new class of meds, a Dal­las biotech with a Phase III kid­ney can­cer drug and a start­up that in-li­censed its lead drug from No­var­tis.

They are all on­col­o­gy fo­cused, high­light­ing the big mon­ey that con­tin­ues to pour in­to all things can­cer re­lat­ed.

Each of these 3 biotechs has been par­tial to the clas­sic biotech start­up game plan, where you flag in­com­ing col­lab­o­ra­tions with the biggest names you can find to work with — while of­ten stay­ing mum about the cash in­volved and/or keep­ing the de­tails about their lead pro­grams un­der wraps.

On­col­o­gy, af­ter all, is an in­tense­ly com­pet­i­tive field. But come the S-1s, se­crets must be spilled.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER